We are live on ! Find out more
IPHA

Innate Pharma
IPHA

11 hedge funds and large institutions have $1.49M invested in Innate Pharma in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.68% less ownership

Funds ownership: 1.18% → 0.5% (-0.68%)

8% less funds holding

Funds holding: 12 → 11 (-1)

21% less capital invested

Capital invested by funds: $1.89M → $1.49M (-$398K)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

60% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 5

Holders
11
Holders Change
-1
Holders Change %
-8.33%
% of All Funds
0.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
5
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$130K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$30.3K
3
TRCT
Tower Research Capital (TRC)
New York
+$6.73K
4
Barclays
Barclays
United Kingdom
+$659

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$965K
2
Optiver Holding
Optiver Holding
Netherlands
-$182K
3
Two Sigma Investments
Two Sigma Investments
New York
-$38K
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$32K
5
Bank of America
Bank of America
North Carolina
-$20.5K

IPHA Hedge Fund Activity: Q4 2022 in Review

11 of the 6,239 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q4 2022, worth a combined $1.49M — down 21% from $1.89M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of IPHA and 2 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 2 added.

The largest buyer was Millennium Management, adding an estimated $130K. The largest seller was BlackRock, exiting entirely with an estimated $965K sold.

  • 11 institutional investors held Innate Pharma (IPHA) as of Q4 2022, down from 12 in Q3 2022.
  • Funds reported $1.49M of Innate Pharma stock for Q4 2022, down 21% quarter-over-quarter.
  • 2 funds opened new Innate Pharma positions in Q4 2022 and 3 closed out, a net change of -1 holder.
  • The largest Innate Pharma buyer in Q4 2022 was Millennium Management, an estimated $130K added.
  • The largest Innate Pharma seller in Q4 2022 was BlackRock, an estimated $965K sold.

Based on aggregated 13F filings for Q4 2022.